Fear expression is reduced after acute and repeated nociceptin/orphanin FQ (NOP) receptor antagonism in rats: therapeutic implications for traumatic stress exposure

Taylor, Rachel M; Jeong, Isaac; May, Matthew; Bergman, Elizabeth M.; Capaldi, Vincent F.; Moore, Nicole L.; Matson, Liana M.; Lowery-Gionta, Emily G.

doi:10.1007/s00213-020-05582-0

Cited by 9 publications

(4 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…showing amelioration of PTSD-associated behaviors (e.g., fear, anxiety, pain) in rodents by both NOP antagonists (Genovese & Dobre, 2017;Taylor et al, 2020;Zhang et al, 2015) and agonists (Adem et al, 2017;Andero et al, 2013).…”

Section: Nociceptin/orphanin Fq Peptide Receptor (Nop) In Anxiety Dis...mentioning

confidence: 99%

“…Stimulation of NOP receptors by nociceptin inhibits neurotransmitter release, including glutamate, GABA, DA, serotonin, and acetylcholine (Schlicker & Morari, 2000); this effect mirrors neurochemical abnormalities that have been associated with PTSD (Kelmendi et al, 2016). However, studies of NOP in animal models of PTSD have been somewhat contradictory (Tollefson et al, 2017), showing amelioration of PTSD‐associated behaviors (e.g., fear, anxiety, pain) in rodents by both NOP antagonists (Genovese & Dobre, 2017; Taylor et al, 2020; Zhang et al, 2015) and agonists (Adem et al, 2017; Andero et al, 2013).…”

Section: Application Areasmentioning

confidence: 99%

See 1 more Smart Citation

Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders

Royse

Lopresti

Mathis

et al. 2022

Journal of Neurochemistry

View full text Add to dashboard Cite

Early applications of positron emission tomography (PET) in psychiatry sought to identify derangements of cerebral blood flow and metabolism. The need for more specific neurochemical imaging probes was soon evident, and these probes initially targeted the sites of action of neuroleptic (dopamine D2 receptors) and psychoactive (serotonin receptors) drugs. For nearly 30 years, the centrality of monoamine dysfunction in psychiatric disorders drove the development of an armamentarium of monoaminergic PET radiopharmaceuticals and imaging methodologies. However, continued investments in monoamine‐enhancing drug development realized only modest gains in efficacy and tolerability. As patent protection for many widely prescribed and profitable psychiatric drugs lapsed, drug development pipelines shifted away from monoamines in search of novel targets with the promises of improved efficacy, or abandoned altogether. Over this period, PET radiopharmaceutical development activities closely parallelled drug development priorities, resulting in the development of new PET imaging agents for non‐monoamine targets. In part two of this review, we survey clinical research studies using the novel targets and radiotracers described in part one across major psychiatric application areas such as substance use disorders, anxiety disorders, eating disorders, personality disorders, mood disorders, and schizophrenia. Important limitations of the studies described are discussed, as well as key methodologic issues, challenges to the field, and the status of clinical trials seeking to exploit these targets for novel therapeutics.

show abstract

Section: Nociceptin/orphanin Fq Peptide Receptor (Nop) In Anxiety Dis...mentioning

confidence: 99%

Section: Application Areasmentioning

confidence: 99%

Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders

Royse

Lopresti

Mathis

et al. 2022

Journal of Neurochemistry

View full text Add to dashboard Cite

show abstract

“…NOP antagonists can serve as drugs for inhibiting the fear response of trauma cuing. It may have beneficial effects on traumatic memory of stress disorder [45].…”

Section: Other Medicationsmentioning

confidence: 99%

Advances in the pathogenesis and pharmacotherapy of acute stress disorder

Wang¹,

Fu²

2022

Int. J. Sci. Res. Arch.

View full text Add to dashboard Cite

Acute stress disorder (ASD) is a kind of mental disease caused by trauma, which will bring heavy burdens to patients themselves, their family, their work and their lives. Once a person who has suffered a trauma develops post-traumatic stress disorder (PTSD), the quality of life of patients will be overall impaired. It is found that the occurrence of stress disorder is related to the overactivation of hypothalamus pituitary adrenal axis (HPA axis). The most commonly used medications for ASD are recommended medications for PTSD, including serotonin reuptake inhibitors (SRIs), second-generation antipsychotics, benzodiazepines, beta blockers, and others. The purpose of this article is to systematically organize and review the possible mechanisms of stress disorder and drugs for treatment of ASD.

show abstract

“…Интересно, что у интактных, то есть не стрессированных животных, изменений в поведении при введении антагониста NOPr не наблюдалось [72]. В тесте "представление хищника" у мышей антагонисты NOPr могут оказывать как анксиолитическое, так и антидепрессивное действие, не затрагивая иные формы поведения [73]. При этом антагонист NOPr SB-612111 оказывает анксиолитическое действие у мышей в стадии истощения ответа на стресс, но не у интактных животных.…”

Section: тревожность: анксиолитический или анксиогенный эффекты стимуunclassified

The role of nociceptin in opioid regulation of brain functions

et al. 2021

View full text Add to dashboard Cite

This review discusses our current knowledge on the nociceptin/orphanin (N/OFQ) system regarding its role in regulation of brain functions. Nociceptin receptor (NOPr) was identified in 1994 [Bunzow et al., 1994; Mollereau et al., 1994]. In 1995 a 17 amino acid endogenous peptide was found to be the high-affinity ligand for the NOPr [Reinscheid et al., 1995]. N/OFQ has a broad spectrum of activity and can act as on opioid-like as well as an anti-opioid peptide. Considering high level of N/OFQ and NOPr mRNA expression in the limbic brain regions, the N/OFQ/NOP system is suggested to be involved in regulation of emotions, resward, pain sensitivity, stress responsibility, sexual behavior, aggression, drug abuse and addiction. However it is still not well understood whether an increased vulnerability to drugs of abuse may be associated with dysregulation of N/OFQ/NOP system. Current review further highlights a need for further research on N/OFQ/NOP system as it could have clinical utility for substance abuse, depression, and anxiety pharmacotherapy.

show abstract

Fear expression is reduced after acute and repeated nociceptin/orphanin FQ (NOP) receptor antagonism in rats: therapeutic implications for traumatic stress exposure

Cited by 9 publications

References 55 publications

Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders

Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders

Advances in the pathogenesis and pharmacotherapy of acute stress disorder

The role of nociceptin in opioid regulation of brain functions

Contact Info

Product

Resources

About